Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2001-03-14
2004-02-24
Smith, Lynette R. F. (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007230, C435S007100, C435S007400, C435S007910, C435S007720, C435S007700
Reexamination Certificate
active
06696262
ABSTRACT:
BACKGROUND OF THE INVENTION
In the following background information is presented relating to methods for screening for the risk of gastric cancer, primarily using pepsinogen I and gastrin-17 determination from a blood sample.
Although the occurrence of new cases of gastric cancer has diminished in the recent years, gastric cancer is still one of the most common malignancies. In Finland, approximately 250 to 300 new cases of cancer/one million people/year are registered. In the age group of people above 50, there are an estimated 2350 cases of stomach cancer, which is about 3 per mille of the age group population (Finnish Cancer Registry—The Institute for Statistical and Epidemiological Cancer Research 1993). In addition to Finland, there is a high gastric cancer incidence in Iceland, South America and especially in Japan.
The prognosis of gastric cancer is usually poor, as there is no specific treatment. Presently the only possibility of successfully treating gastric cancer is its early detection and total removal surgically.
Gastric cancer does not necessarily give any symptoms in its early stages. The late appearance of symptoms naturally delays the patient from seeking treatment. On the other hand, the clinical findings in the early stage of gastric cancer are often non-specific. The primary diagnostic method for gastric cancer is presently gastroscopy and biopsies, cell and aspiration cytology associated therewith. As routine gastroscopies are carried out in order to examine symptoms, such as pain in the upper abdomen or bleeding of the gastrointestinal tract, a symptomatic gastric cancer discovered in this manner is often already far advanced and thus inoperable. Attempts have also been made at improving primary diagnostics with various immunological methods, but no sufficiently specific immunological method has been successfully developed.
It is a primary object to find the means by which it would be possible to identify within the general population easily and with moderate costs those symptomless persons which might be suffering from gastric cancer in its initial stages. After identification these persons should immediately be examined by gastroscopy. At the same time those persons could be identified which exhibit premalignant gastric changes which need to be followed up.
Gastric cancer can be preceded by a number of different gastric diseases or conditions (so called precancerous conditions), which are chronic atrophic gastritis, pernicious anaemia, ventricular ulcer, gastric polyposis and the Ménétrier disease (giant hypertrophic gastritis). Clearly identifiable changes of the mucosa are dysplasia and adenoma. The said conditions are associated with an approximate 4 to 5 fold relative cancer risk, as compared to the general population. It has been established that in almost all diseases the risk is mediated over chronic atrophic gastritis.
Chronic gastritis means a prolonged inflammatory condition of the gastric mucosa. The disease can coarsely be divided into the so-called superficial and the atrophic form. In superficial gastritis, the inflammatory cell infiltration is concentrated below the surface epithelium. In case the inflammation progresses and diffuses between the specific gastric secretory glands, one refers to chronic atrophic gastritis. In such a case, the normal glandular structures of the gastric mucosa are at least partly substituted by metaplastic changes.
The relative risk of gastric cancer in patients suffering from atrophic gastritis in the corpus area of the stomach, has been estimated, as calculated from the Finnish cancer statistics, to be about 4- to 5-fold as compared to persons having a healthy mucosa. In addition, there is a risk for falling ill with pernicious anaemia due to intrinsic factor deficiency and B12 vitamin absorption disturbance. In severe atrophy of the antrum area, the risk is even 18-fold. If atrophic changes appear both in the antrum and the corpus area (pangastritis), the risk can increase to even 90-fold (Sipponen, Kekki, Haapakoski, Ihamäki & Siurala 1985).
REFERENCES:
patent: 6156525 (2000-12-01), Furuta
Westerveld, BD et al, Cancer , vol. 59, 952-958, 1987.*
Webb, PM e tal, Gastroenterology, Nov. 1994, vol. 107(5), pp. 1335-1344.*
Maaroos, HI et al, Scand. J. Gastroenterol. vol. 29, pp. 532-536, 1994.*
Ardill, JES et al, Regulatory Peptides, vol. 40(2), pp. 109, year:1992, abstract only.*
Westerveld, BD et al, Pepsinogens in Man: Clinical and Genetic Advances, pp. 201-212, 1985.*
Petersen, B, Scand. J. Gastroenterol. (Norway), 1983, vol. 18(5), pp. 613-615.*
Petersen, B et al, Sancd. J. Gastroenterol..vol. 18, pp. 635-641, 1983.*
Walker, K etal, Clinical Therapeutics, vol. 7(6), pp. 704-716, 1985.*
Chen, TS et al, Am. J. Gastroenterol., Sep. 1994, vol. 89(9), pp. 1511-1514.*
Deprez, PH et al, Regulatory peptides, vol. 40(2), pp. 134, 1992.*
Janssen, M et al, Journal of Rheumatology, vol. 32, pp. 371-374, 1993.*
Karnes, WE et al, Gastroenterology, vol. 101, pp. 167-174, 1991.*
Mulholland, G et al, Gut, vol. 34, 1993, pp. 757-761 (best copy available).*
Newell, DG etal, Infect. Dis., vol. 3, pp. 1-6, 1989.*
Plebani, M, Crit. Rev. Clin. Lab. Sci, vol. 30(3), pp. 273-328, 1993.*
Sipponen, P et al, J. Clin. Pathology, vol. 45(4), pp. 319-323, 1992.*
Wu, WC et al, American J. Gastroenterology, vol. 89(8), p. 1361, 1994, abstract 304.*
Vol. 26, No 186, 1991, K. Varis et al., “Serum Pepsinogen I and Serum Gastrin in the Screening of Atrophic Pangastritis with High Risk of Gastric Cancer”, pp. 117-123, see “Discussion”, Scan. J. Gastroenterol.
Scand J Gastronenterol, vol. 26, No 186, 1991, M. Kekki et al, “Serum Pepsinogen I and Serum Gastrin in the Screening of Severe Atrophic Corpus Gastritis” pp. 109-116.
Cancer, vol. 59, 1987, B.D. Westerveld et al, “Clinical Significance of Pepsinogen A Isozymogens, Serum Pepsinogen A and C Levels, and Serum Gastrin Levels” pp. 952-958.
Dialog Information Service, file 154, Medline, Dialog accession No. 07951582, Medline accession No. 92089582, Farinati F. et al.: “Pepsinogen A/pepsinogen C or pepsinogen A multiplied by gastrin in the diagnosis of gastrin cancer”, Ital J Gastroenterol (Italy) May 1991, 23 (4) p194-6.
Digestive Disease and Sciences, Vol 29, No 9, Sep. 1984, Haruka Sasaki et al, “Low Acid Output in Pima Indians A Possible Cause for the Rarity of Duodenal Ulcer in this Population”, pp. 785-789.
Dialog Information Service, file 154, Medline, Dialog accession No. 08849602, Medline accession No. 94164602, Lin JT et al: “Serum levels of pepsinogen I and gastrin in gastric carcinoma: the influence ofHelicobacter pyloriinfection and tumor characteristics”, Hepatgastroenterology (Germany) Dec. 1993, 40 (6) p600-3.
Dialog Information Service, file 154, Medline, Dialog accession No. 08512746, Medline accession No. 93222746, Sitas F. et al: “Serum anti-Helicobactor plyoriIgG antibodies and pepsinogens A and C as serological markers of chronic atrophic gastritis”, Cancer Epidemiol Biomarkers Prev 1993, 2 (2) p119-23.
Clin. Chem., vol. 31, No. 1, 1985, Goran Lindstedt et al, “Analytical and Clinical Evaluation of a Radioimmunassay for Gastrin”.
Int. J. Cancer, vol. 35, 1985, Pentti Sipponen et al., “Gastric Cancer Risk in Chronic Atrophic Gastritis: Statistical Calculations of Cross-Sectional Data” pp. 173-177.
Clinica Chimica Acta, vol. 162, 1987, Shih Che Huang et al, “Enzyme-linked immunosorbent assay of serum pepsinogen I” pp. 85-96.
Scan J Clin Lab Invest, Vol 47, 1987, Gerard Pals et al, “Enzyme-linked immunosorbent assay and radioimmunoassay of serum pepsinogen A” pp. 29-33.
Clinica Chimica Acta, vol. 175, 1988, Shih Che Huang et al, “Enzyme-linked immunsorbent assays for serum pepsinogens I and II using monoclonal antibodies—with data on peptic ulcer and gastric cancer” pp. 37-50.
Chemical Abstracts, vol. 119, 1993, 6252f, “Clinical Application of the determination of serum pepsinogens I and II levels and serum gastrin levels in gastroduodenal diseases”, Nishi, S. et al. Wakayama Igaku 1992 43(2), 221-8 (Japan).
Tiivistelmä julkaisusta Jpn J Cancer Res (Japan), 84(8) s844-51,
Biohit Oyj
Portner Ginny Allen
Smith Lynette R. F.
LandOfFree
Method for screening the risk of gastric cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for screening the risk of gastric cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for screening the risk of gastric cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3324429